Table 4.

FGFR inhibitors, target and main clinical indications or trials.

Name (Code) Trade Name	Targets	Approved Clinical Indications or Clinical Trial Study
Erdafitinib (JNJ-42756493) Balversa	FGFR1/2/3/4	Urothelial bladder cancer
Nintedanib (BIBF-1120) Vargatef	FGFR1/2/3	Idiopathic pulmonary fibrosis, NSCLC
Pemigatinib (INCB054828) Pemazyre	FGFR1/2/3	Cholangiocarcinoma
Rogaratinib (BAY 1163877)	FGFR1/2/3	Under development in SQCLC (NCT03762122), breast cancer (NCT04483505), urothelial carcinoma (NCT03473756), sarcoma GIST (NCT04595747), and gastric cancer (NCT04077255)
Vofatamab (B-701)	FGFR 3	Under development in urothelial carcinoma (NCT03123055, NCT02401542)
Infigratinib (BGJ398)	FGFR1/2/3	Under development in urothelial carcinoma (NCT04197986), breast cancer (NCT04504331), cholangiocarcinoma (NCT03773302), and glioblastoma (NCT04424966)
Derazantinib (ARQ 087)	FGFR1/2/3	Under development in urothelial carcinoma (NCT04045613), gastric cancer (NCT04604132) and cholangiocarcinoma (NCT03230318)
AZD4547	FGFR1/2/3	Under development in NSCLC (NCT01824901), breast cancer (NCT01202591), gliomas (NCT02824133), urothelial carcinomas (NCT02546661) and gastro-esophageal cancer (NCT01457846)
Debio 1347	FGFR1/2/3	Under development in breast cancer (NCT03344536) and other solid tumors (NCT03834220)